key: cord-1000164-4pcqheow authors: Taylor, A.; Cushing, A.; Dow, M.; Anderson, J.; McDowell, G.; Manthe, M.; Padmanabhan, S.; Burns, S.; McGineess, P.; Lowe, D. J.; Carlin, C. M. title: Sustained patient use and improved outcomes with digital transformation of a COPD service: RECEIVER trial and DYNAMIC-SCOT COVID-19 scale-up response. date: 2022-04-05 journal: nan DOI: 10.1101/2022.04.04.22273427 sha: bde43bd695fa396eb7d1a538a34ebdd06b81d3a4 doc_id: 1000164 cord_uid: 4pcqheow Introduction LenusCOPD has been co-designed to enable digital transformation of COPD services for proactive preventative care. Patient-facing progressive web application, clinician dashboard and support website integrate patient-reported outcomes (PROs), self-management resources, structured clinical summary, wearable and home NIV data with asynchronous patient-clinician messaging. We commenced the implementation-effectiveness observational cohort RECEIVER trial in September 2019, with the primary endpoint of sustained patient usage and secondary endpoints including admissions, mortality, exacerbations, service workload and quality of life. We paused recruitment in March 2021 and provided LenusCOPD as routine care in the 'DYNAMIC-SCOT' COVID-19 response service scale-up. Methods 83 RECEIVER trial participants and 142 DYNAMIC-SCOT participants had completed minimum 1 year follow-up when we censored data on 31st August 2021. We established a control cohort with 5 patients matched per RECEIVER participant from de-identified contemporary routine clinical data. Results Sustained patient app utilisation was noted in both cohorts. Median time to admission or death was 43 days in control, 338 days in RECEIVER and 400 days in DYNAMIC-SCOT participants who had had a respiratory-related admission in the preceding year. The 12-month risk of admission or death was 74% in control patients, 53% in RECEIVER and 47% in the DYNAMIC-SCOT sub-cohort participants. There was a median of 2.5 COPD exacerbations per patient per year with stable quality of life across follow up and a manageable workload for clinical users. Conclusions A high proportion of people continued to use the co-designed LenusCOPD application during extended follow-up. Outcome data supports scale-up of this digital service transformation. Chronic obstructive pulmonary disease (COPD) affects over 1.2 million people in the UK. COPD exacerbations account for one in eight UK hospital admissions, with a projected annual cost to NHS UK of £2.5bn by 2030. People with COPD prioritise the avoidance of exacerbations and resultant hospitalisations(1) The Patient Charter for COPD (March 2021), called for proactive, preventative management to reduce the risk of exacerbations and premature death (2) . Strategies and services that support guideline-based care and self-management of COPD have been shown to reduce exacerbations and hospitalisations, improve health-related quality of life measures, improve long term outcomes and decrease healthcare and social costs (3) (4) (5) (6) (7) . However, availability, accessibility, uptake and delivery of these interventions are highly variable (8) . Digital transformation with co-designed digital tools offers the opportunity to expand accessibility and engagement with these COPD interventions (9, 10) . Positive results have been seen from individual studies which have used internet/app based digital self-management interventions for COPD (11) (12) (13) . Other studies have shown neutral or negative impact. The format and delivery of the interventions are variable, extensive heterogeneity between studies and high risk of bias means that systematic reviews have been unable to collate evidence of significant, persisting benefit of digital interventions (14) . Access and familiarity with digital interventions has been accelerated by the COVID-19 pandemic, including in older adults(15). Improved usability and enhanced datasharing enabled by cloud-based computing presents opportunities to improve on previous digital COPD interventions. Emerging innovations, including connected therapies (e.g., smart inhalers, home NIV), wearable sensors and AI-based analytics create possibilities for additional COPD care-quality improvements, if an infrastructure to implement and evaluate these can be established. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint We conceived and commenced the 'DYNAMIC' (Digital innovation with remote data management and machined-learning algorithms to integrate care of high-risk COPD) project in September 2018. Patient participatory co-design with cycles of user experience testing was used to develop the "LenusCOPD' patient and clinician web applications and support website. The anticipation was that service transformation based on this intervention would achive a reduction in respiratoryrelated admissions and occupied bed days in a high-risk COPD cohort, if sustained patient utilisation and supported co-management could be delivered. We commenced the 'RECEIVER' (remote management of COPD: evaluating the implementation of digital innovations to enable routine care) trial to evaluate this intervention in September 2019, with a primary endpoint of participant use of the LenusCOPD application (16) . We selected an implementation-effectiveness observational cohort design, to allow for adaptations to the intervention and the implementation strategy based on planned interim evaluations (17) . We had to pause RECEIVER recruitment at month 6 of 12 at the start of the first UK COVID-19 lockdown (March 2020). Based on positive interim evaluations (sustained patient app usage) we elected to continue RECEIVER follow-up in recruited participants and adapt the trial resources to rapidly scale-up our provision of the LenusCOPD-based. The aim was to mitigate COVID-19 related service interruptions and enhance COPD co-management in vulnerable individuals. In May 2020, we sent an initial batch of text-message invitations to register with the service to people with COPD who were previously known to secondary care teams. This was supported by a social media awareness campaign run by NHS GG&C Communications Team. We continued with the evaluation framework established for RECEIVER in this We can now report on the primary outcome (patient utilisation of the app) and key 1-year secondary outcomes for the people who were recruited to RECEIVER (Sept 2019 -March 2020) and in the first cohort of people who were onboarded to the service in May-August 2020 (DYNAMIC-SCOT scale-up implementation cycle 1) who had completed minimum 12 months of follow-up when data was censored on 6 31 st August 2021. To support these evaluations, we matched each RECEIVER participant with 5 contemporary control patients from NHS GG&C SafeHaven's COPD dataset. The objectives of this hybrid implementation-effectiveness trial and service evaluation were to determine the feasibility and utility of digital transformation of an NHS COPD service including: • establishing if participants would continue using the LenusCOPD patient application (feasibility, utilisation). • determining the impact of the digital transformation on outcomes including COPD-related hospital admissions, participant mortality, communitymanaged COPD exacerbations, quality of life, and measurements of clinician service workload. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022 People were excluded from RECEIVER and DYNAMIC-SCOT if they had a communication barrier precluding the use of the COPD digital service. The service consists of a patient app, a clinician app/dashboard and support website ( Figure 1 ), with the same components utilised by both RECEIVER and DYNAMIC-SCOT scale-up participants. Additional information on "how it works" is available at https://support.nhscopd.scot. Further details of the intervention components, data processing and data storage are in the supplementary methods. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint The primary endpoint for RECEIVER trial was the proportion of enrolled participants with high-risk COPD who utilised remote management in a digital service model. Daily COPD assessment test and symptom diary questions, weekly MRC and healthcare episode questions, and monthly quality of life questions (EQ-5D-5L questionnaire) were captured in the LenusCOPD patient app. We pre-planned 3- participants. Analyses of these datasets, the detailed PRO insights and the associated AI model development are ongoing and will be reported subsequently. Baseline and follow-up demographic and physiological data from electronic health records is recorded in the LenusCOPD clinician dashboard. The index date for study participants is defined as the date on which they completed registration with LenusCOPD and had access to patient web application. NHS GG&C SafeHaven has a detailed de-identified dataset of demographic, laboratory, prescribing, hospital admission and mortality data. We followed relatable evaluations using routine clinical data by establishing a control cohort containing 5 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint patients matched to each RECEIVER trial participant(18). We selected matching criteria of diagnosis of COPD, age, sex and an index respiratory-related hospital admission within the 14-day window of the reference trial participant's index date. We excluded duplicate control patients or those who had been subsequently onboarded to the COPD digital service. There is no reference data on uptake or sustained usage of a COPD patient app to allow calculation of a sample size. We set a screening target of 400 patients over 12-month period for the RECEIVER trial, based on previous experience (19) . Survival to admission, death, and admission or death was estimated in the RECEIVER, DYNAMIC-SCOT scale-up, and control cohorts using Kaplan-Meier survival analysis with log rank test. To compare survival between cohorts, hazard ratios (HRs) and 95% lower/upper confidence intervals (CIs) were calculated using Cox regression. Wilcoxon signed-rank tests were used to compare the number of recorded admissions and occupied bed days in the 12-month period before and after index date. The significance and effect size of observed changes was determined for each cohort. Statistical analyses were performed using R Studio Patients and members of the public were involved throughout the planning and conduct of this research. Semi-structured interviews were conducted by the DYNAMIC development team to understand patient's experience of their condition and allow iterative co-design of the LenusCOPD tools. Pre-study testing yielded an average system usability score of 80/100, indicating high usability and learnability. The research questions and RECEIVER study design were informed by insights . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint gained from these interactions and from published data on the priorities of people with COPD. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The participant flow diagram details the recruitment and invitation strategies, Survival data is summarised in Table 2 Similar differences were noted with prolonged time to admission in the intervention cohorts when considering this endpoint alone (Table 2, Figure 4C ). No significance differences in time to admission survival metrics was seen in exploratory analyses conducted on RECEIVER participants stratified by 7-day rolling average PRO completion quartile or by SIMD category ( Supplementary Figures 3 and 4) . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint Mortality 12-month all-cause mortality was lower in the intervention cohorts than in the control cohort (Table 2; Figure 4B ). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint We compared baseline and final CAT and EQ-VAS scores prior to censor date from participants who had completed >1 set of these PROs (Figure 7) . There was a rise in median CAT score from 23/40 to 26/40 over the study follow-up period in both RECEIVER and scale-up cohorts (p= 0.008). There was no significant change in overall EQ-VAS scores across RECEIVER cohort, with a small reduction (median from 50 to 46.5) in Scale-up participants across follow-up. Variations in these and other captured PRO scores including per-patient level time-series with COPD events will be explored in subsequent analyses. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. These outcome findings are consistent with several previous studies of telehealth, remote-monitoring and supported self-management-based COPD service transformation, and contrast with individual studies and systematic reviews which have shown muted, no effect or a negative impact of comparable interventions on COPD events (11) (12) (13) (14) (20) (21) (22) (23) . Key differentiators for this LenusCOPD-enabled digital transformation include extensive pre-trial patient and clinician co-design (incorporating lessons learned from previous investigations), verified COPD diagnosis, daily prompts to complete PROs, asynchronous patient-clinician messaging, clinician option to activate individualised rescue pack advice in the patient app, and use of the service alongside routine care contacts rather than prespecified regular data reviews with triggered patient contact. The sustained participant utilisation of the patient app may also account for some of the apparent outcome benefits. Incorporating follow up beyond one year is also a strength compared to most other COPD intervention studies (20) , and we will be able to report longer term follow-up subsequently. Only 41 of 283 potential RECEIVER participants lacked technology access which was lower than anticipated and is improved compared with previous reports (24) . Service uptake following a single unsolicited text message in the DYNAMIC-SCOT . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint The strengths of this study include the selection of an observational implementation-effectiveness methodology, which allowed us to pivot the implementation to assist COVID-19 pandemic response. The use of contemporary routine clinical data to derive a control cohort rather than a randomised design allowed us to maximise participant numbers using the intervention for the interim and final primary endpoint analyses. Whilst the lack of a randomised control arm is an important caveat, the control cohort derivation with an index date and outcome follow-up time period matched to RECEIVER participants reduces potential bias from seasonality and COVID-19 pandemic impacts on COPD event rates. Conclusions from this study have to be tempered by residual biases and confounders, including incomplete clinical information available for the control cohort and reduced integrity of matching for the control:DYNAMIC-SCOT comparison. Reduced event rates were seen in the control cohort across COVID-19 pandemic, this is in line with other investigations and suggests that this cohort is representative (26, 27) . The increased time to first events in the survival analyses and reduced median admission rates in the intervention cohorts provide a reassuring safety signal and encouraging hypothesis-generating utility data. The admission and community exacerbation event rates in the intervention cohorts provide further safety data: they are reduced when compared with historical NHS GG&C data, and similar to recent published data. It is therefore unlikely that reduced admission events in the intervention cohorts relate to delays from inappropriate community management, or that the intervention leads to unsupervised overuse of corticosteroid/antibiotic courses. The reduced median occupied bed day rate profiles in the intervention cohorts are particularly encouraging. COPD is estimated to consume €48.4 billion annually in EU healthcare costs, with the majority of those costs arising from exacerbation and admission management (28) . Scaling a service intervention which reduces respiratory-related occupied bed day rates in people with COPD should be highly cost-effective. The Lenus-COPD based service transformation was co-designed with an experienced COPD multidisciplinary team and adopted "on top" of the team's . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint proven capabilities (29, 30) . COPD prevalence and burden is higher than population average in our predominantly urban health board, reflecting public health factors. The impaired survival and high admission event rates in our control cohort highlight a substantial persisting care-quality gap. We hope to address this this by scaling our digital transformation work in our own organisation, with continued evaluation and reporting. Our COPD digital service transformation strategy and evaluation framework should be adapted by different healthcare organisations and different territories, to reflect local services and clinical priorities. The data from the RECEIVER trial and DYNAMIC-SCOT COVID-19 response service scale-up support expansion of digital transformation of COPD services using codesigned tools such as LenusCOPD. The innovative implementation-effectiveness design with supporting contemporary matched routine clinical data allowed rigorous evaluation of an intervention to be combined with adjustments to the intervention or implementation strategy based on adoption experience, or if the adoption scenario changes. The LenusCOPD-based service transformation co-designed in the DYNAMIC project provides wide-ranging opportunities to improve our understanding of COPD and achieve the outcomes -reduced exacerbations and associated admissions -which people living with COPD most value. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint Table 2 12-month survival analyses: respiratory-related admissions and all-cause mortality. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint LenusCOPD clinician dashboard front page with sample data provides key data for "at a glance" review of patient status. Key patient app screens -opening page, weekly PRO question for COPD event detection, sample patient-clinician messaging with banner noting service purpose and emergency contacts -are included. Support website (https://support.nhscopd.scot) includes registration page for patient app, service explanation videos and COPD support content including selfmanagement videos. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint Participant flow diagram. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint Figure 4 Kaplan-Meier survival plots of time to readmission or death (A), death (B) or readmission (C) from index/onboarding date until 31 st August 2021 in control, RECEIVER and DYNAMIC-SCOT cohorts (S1, subdivided by occurrence or absence of a respiratory-related admission in the year prior to onboarding). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint Figure 5 Violin boxplots summarising COPD-related hospital admission and occupied bed days in the year prior to and year following index/onboarding date in the 4 patient cohorts. Improved profiles are noted in the RECEIVER and Scale-up (admission previous year) intervention cohorts following onboarding compared to control cohort. Data are presented for patients alive at 12 months. No significant differences were noted in data distributions when including or excluding deceased patients (see supplementary content). Red dot = median. Horizontal bar = mean. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint Figure 6 Violin boxplots summarising community-managed (clinician-assessed or self-treated) exacerbation events captured in the LenusCOPD patient app in the year following onboarding in the RECEIVER, DYNAMIC-SCOT scale-up intervention cohorts, and the sub-cohort of DYNAMIC-SCOT participants who had a respiratoryrelated admission in the year prior to onboarding (Scale-up*). Red dot = median. Horizontal bar = mean. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Red dot = median. Horizontal bar = mean. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273427 doi: medRxiv preprint A systematic review of how patients value COPD outcomes A Patient Charter for Chronic Obstructive Pulmonary Disease The effects of chronic obstructive pulmonary disease self-management interventions on improvement of quality of life in COPD patients: A meta-analysis Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD Program of Integrated Care for Patients with Chronic Obstructive Pulmonary Disease and Multiple Comorbidities (PIC COPD+): a randomised controlled trial Gold Reports. Global Initiative for Chronic Obstructive Lung Disease -GOLD Interventions to increase referral and uptake to pulmonary rehabilitation in people with COPD: a systematic review A Systematic Review of Healthcare Applications for Smartphones Living with asthma and chronic obstructive airways disease: Using technology to support selfmanagement -An overview eHealth Program to Reduce Hospitalizations Due to Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Retrospective Study A randomised controlled feasibility trial of E-health application supported care vs usual care after exacerbation of COPD: the RESCUE trial Self-Management Support Using a Digital Health System Compared With Usual Care for Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial Digital interventions for the management of chronic obstructive pulmonary disease. Cochrane Database Syst Rev Remote-Management of COPD: Evaluating the Implementation of Digital Innovation to Enable Routine Care (RECEIVER): the protocol for a feasibility and service adoption observational cohort study Effectivenessimplementation Hybrid Designs: Combining Elements of Clinical Effectiveness and Implementation Research to Enhance Public Health Impact. Med Care Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease. Cochrane Database Syst Rev Telehealth Interventions to Support Self-Management of Long-Term Conditions: A Systematic Metareview of Diabetes, Heart Failure, Asthma, Chronic Obstructive Pulmonary Disease, and Cancer Unexpected Harm From an Intensive COPD Intervention Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial Uptake of telehealth implementation for COPD patients in a high-poverty, inner-city environment: A survey Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature Assistive technologies for home NIV in patients with COPD: feasibility and positive experience with remote-monitoring and volume-assured auto-EPAP NIV mode Measuring the impact of a Chronic Obstructive Pulmonary Disease Community Respiratory Programme on emergency admissions to hospital: a controlled interrupted time series analysis